rupiya.io
⠋Loading...
0%
❯ Analyzing price movements...
Lupin Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Lupin Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹12,770 Cr | ₹14,256 Cr | ₹17,367 Cr | ||||||||
| Expenses | ₹9,146 Cr | ₹10,564 Cr | ₹12,865 Cr | ||||||||
| Operating Profit | ₹3,624 Cr | ₹3,691 Cr | ₹4,502 Cr | ||||||||
| OPM % | 28.0% | 26.0% | 26.0% | ||||||||
| Other Income | ₹235 Cr | ₹184 Cr | ₹106 Cr | ||||||||
| Depreciation | ₹435 Cr | ₹487 Cr | ₹912 Cr | ||||||||
| Interest | ₹10 Cr | ₹59 Cr | ₹153 Cr | ||||||||
| Profit Before Tax | ₹3,415 Cr | ₹3,329 Cr | ₹3,543 Cr | ||||||||
| Tax | ₹3,415 Cr | ₹3,329 Cr | ₹3,543 Cr | ||||||||
| Net Profit | ₹2,444 Cr | ₹2,270 Cr | ₹2,565 Cr | ||||||||
| EPS (₹) | 53.5 | 50.2 | 56.6 | ||||||||
| Dividend Payout % | 14% | 15% | 13% |
Register free to see 8 more years.
| Quarter | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹4,430 Cr | ₹4,814 Cr | ₹5,039 Cr | ₹5,197 Cr | ||||||||
| Expenses | ₹3,852 Cr | ₹3,958 Cr | ₹4,121 Cr | ₹4,159 Cr | ||||||||
| Operating Profit | ₹578 Cr | ₹856 Cr | ₹918 Cr | ₹1,038 Cr | ||||||||
| OPM % | 13.0% | 18.0% | 18.0% | 20.0% | ||||||||
| Depreciation | ₹264 Cr | ₹235 Cr | ₹248 Cr | ₹257 Cr | ||||||||
| Interest | ₹93 Cr | ₹86 Cr | ₹81 Cr | ₹74 Cr | ||||||||
| Net Profit | ₹242 Cr | ₹453 Cr | ₹495 Cr | ₹619 Cr | ||||||||
| EPS (₹) | 5.2 | 9.9 | 10.8 | 13.5 |
Register free to see 8 more quarters.
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹90 Cr | ₹90 Cr | ₹90 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹8,784 Cr | ₹11,073 Cr | ₹13,407 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹537 Cr | ₹7,178 Cr | ₹7,966 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹3,642 Cr | ₹3,957 Cr | ₹4,749 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹13,054 Cr | ₹22,298 Cr | ₹26,212 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹4,368 Cr | ₹8,717 Cr | ₹11,033 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹1,658 Cr | ₹16 Cr | ₹2,136 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹6,451 Cr | ₹10,862 Cr | ₹10,910 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹13,054 Cr | ₹22,298 Cr | ₹26,212 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 8 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2016 | ₹2,733 Cr | ₹-1,034 Cr | ₹-197 Cr | — |
| Mar 2017 | ₹-382 Cr | ₹-6,769 Cr | ₹5,836 Cr | — |
| Mar 2018 | ₹4,114 Cr | ₹-2,527 Cr | ₹433 Cr | — |
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 8 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.53% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +1.47% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -3.21% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +26.02% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +8.24% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.